Experimental cancer injection shows promise but trial ends early
NCT ID NCT04725331
First seen Nov 21, 2025 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tested an experimental drug called BT-001, injected directly into tumors, either alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (like melanoma, lung, or breast cancer). The goal was to see if it was safe and could shrink tumors. The trial was stopped early, but data from 31 participants helps researchers understand safety and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Clinique Universitaire Saint-Luc
Brussels, 1200, Belgium
-
Hôpital Saint-Louis AP-HP
Paris, 75010, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.